Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01563107 · ClinicalTrials.gov registry record · NA

Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome

A NA study of Postural Orthostatic Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center.

Completed
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT01563107: Completed NA study of Postural Orthostatic Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center.

NCT01563107 is a NA study of Postural Orthostatic Tachycardia Syndrome that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 38 participants, below the 9,241-participant average among 11 other Postural Orthostatic Tachycardia Syndrome trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01563107, a NA study of Postural Orthostatic Tachycardia Syndrome, has completed, sponsored by Vanderbilt University Medical Center.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

Patients with Postural Tachycardia Syndrome (POTS) may not adequately expand their plasma volume in response to a high sodium diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal dopamine (DA), may be impaired in POTS and may respond inappropriately to changes in dietary sodium. The investigators propose that the changes in urinary sodium and dopamine excretion caused by consuming low-sodium and high-sodium diets will be different between patients with POTS and healthy volunteers. The purpose of this study is to determine (1) whether changes in dietary sodium level appropriately influence sodium excretion in POTS; (2) whether changes in dietary sodium level appropriately influence DA excretion in POTS; (3) whether a high dietary sodium level appropriately expands plasma volume in POTS; and (4) whether patients with POTS have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.

Primary Outcome

Amount of sodium excreted in urine over 24hr ending on Day 7

Conditions Studied

Postural Orthostatic Tachycardia Syndrome

Interventions

  • RADIATION Plasma Volume
  • PROCEDURE Exercise Capacity Test - Bicycle
  • PROCEDURE Posture Study

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2012-03
Est. Completion 2020-12
Phase NA
Vanderbilt University Medical Center

677 total trials

What the finished NCT01563107 record still lists

NCT01563107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 9,241-participant average among 11 other Postural Orthostatic Tachycardia Syndrome trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Postural Orthostatic Tachycardia Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Plasma Volume is the first listed.

NCT01563107 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT01563107 about?

NCT01563107 is a clinical study titled "Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome". Patients with Postural Tachycardia Syndrome (POTS) may not adequately expand their plasma volume in response to a high sodium diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal dopamine (DA), may be impaired in POTS and may respon...

What is the current status of trial NCT01563107?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2012-03. Estimated completion is 2020-12.

What conditions does trial NCT01563107 study?

This clinical trial studies the following conditions: Postural Orthostatic Tachycardia Syndrome.

What interventions are being tested in trial NCT01563107?

The interventions under investigation include: Plasma Volume (RADIATION), Exercise Capacity Test - Bicycle (PROCEDURE), Posture Study (PROCEDURE).

Who is sponsoring clinical trial NCT01563107?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01563107 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Postural Orthostatic Tachycardia Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01563107's enrollment target sits among peer trials

38 9th of 11 higher than 3 of 11 other Postural Orthostatic Tachycardia Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Postural Orthostatic Tachycardia Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01563107, the US trial registry maintained by the National Library of Medicine. NCT01563107 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.